Vaxart (VXRT) announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

The Department of Health and Human Services, headed by RFK Jr., is responding to reports that the CDC will begin researching ...

The Company now also plans to submit a label extension application to the UK MHRA. Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded ...

(Reuters) -A federal judge ruled in favor of Merck (NSE: PROR) in litigation accusing it of concealing the risks of Gardasil, ...

Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...

Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI12, with support from the EU Horizon Europe program ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus ... and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway ...

Valneva is focused on expanding the vaccine's label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI 12, with support from the EU Horizon Europe program, ...

Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI 12, with support from the EU Horizon Europe program, ...

The Company now also plans to submit a label extension application to the UK MHRA. Valneva is focused on expanding the vaccine's label and access. In the third quarter of 2024, the Company ...